Auna S.A. (AUNA)

Executive Summary / Key Takeaways

• Mexico's operational stabilization after AunaWay implementation challenges sets up a compelling 2026 margin recovery story: After physician disruption and revenue declines in 2025, Mexico operations have stabilized with Q4 revenues unchanged sequentially, surgery volumes growing for two consecutive quarters, and new ISSSTELEON contract terms providing a 30% price increase and pharma control—implying 200+ basis points of margin recovery potential.

• Peru's predictable growth engine provides a stable foundation while Mexico recovers: With 14% EBITDA growth, record-low 48.5% oncology MLR , and the 2028 Trecca project poised to add $200M+ in annual revenue, this segment operates with high predictability and de-risks the investment thesis.

• $825 million debt refinancing transforms the capital structure and enables aggressive growth: Interest costs dropped 100+ basis points, maturities extended, and free cash flow surged 35% to PEN 582 million, funding the $500 million Mexico expansion plan and supporting management's 3x leverage target.

• Oncology specialization drives high-margin growth and competitive differentiation: Mexico oncology revenues jumped 35% in Q4, Peru's oncology MLR fell for six consecutive quarters, and the integrated platform model creates network effects that regional competitors cannot replicate—implying sustainable pricing power.

• Key risk is Mexico execution; key catalyst is Sojitz partnership: While 2026 guidance of 12% revenue and EBITDA growth depends on Mexico's recovery, the Sojitz (8001.T) MOU offers external validation and potential capital for high-teens growth, making Q1 2026 volume trends the critical variable for stock performance.

Setting the Scene: The AunaWay Model's Latin American Healthcare Revolution

Auna S.A., founded in 1989 and headquartered in Luxembourg, has evolved from a regional hospital operator into a vertically integrated healthcare platform spanning Mexico, Peru, and Colombia. The company's core strategy revolves around the "AunaWay" model—a disruptive approach designed to modernize and integrate patient care across Spanish-speaking Latin America. The significance lies in the fact that Latin American healthcare suffers from fragmentation, inconsistent quality, and low insurance penetration, creating a massive addressable market for a standardized, outcome-focused model.

The industry structure reveals why Auna's integrated approach is compelling. Traditional healthcare in these markets operates in silos: hospitals, clinics, and payers function independently, creating inefficiencies. Auna's model breaks these barriers by combining facilities with prepaid health plans, enabling care coordination and data-driven decision-making. This positions Auna as a healthcare ecosystem builder, capturing value across the entire patient journey.

Auna's geographic diversification is strategically crucial. Mexico represents the largest market with significant growth potential, while Peru functions as the company's best-practice laboratory. Colombia serves as a cash flow optimization story, where risk-sharing contracts mitigate regulatory and payer risks. This three-pillar structure means that weakness in one geography does not collapse the entire thesis—a critical risk mitigation that pure-play competitors lack.

The competitive landscape highlights Auna's differentiation. Regional players like Clínica Internacional in Peru, Christus Muguerza and Hospital Ángeles in Mexico, and Fundación Santa Fe de Bogotá operate single-country, hospital-centric models. Auna's multi-country integrated platform creates scale advantages in procurement, technology deployment, and physician recruitment that localized competitors cannot match. More importantly, Auna's prepaid health plan membership generates recurring revenue and patient volume that traditional hospitals must fight for daily.

Technology, Products, and Strategic Differentiation: The AunaWay Advantage

The AunaWay model's disruption begins with physician-supplier relationships. Traditional Latin American healthcare relies on fragmented physician networks with opaque pricing. Auna's model standardizes these relationships through pre-negotiated rates, integrated IT systems, and outcome-based incentives. This created short-term friction in Mexico—physicians adjusted to the economic impact of supplier changes, causing temporary volume declines—but the long-term result is a more scalable and profitable operation. The 2025 Mexico challenges were a known implementation hurdle that ultimately strengthens Auna's competitive position by aligning physician incentives with the platform.

Oncology specialization represents Auna's primary growth engine and moat. The OncoSalud health plans in Peru and Oncocenter network in Mexico target high-complexity, high-margin services where outcomes are the priority. In Q4 2025, Mexico oncology revenues grew 35% sequentially, while Peru's oncology MLR hit a record-low 48.5%—meaning Auna spends less than half of premium revenue on medical costs. This matters because oncology patients require longitudinal care across multiple touchpoints, perfectly suited to Auna's integrated model. Competitors treating oncology as just another service line cannot achieve these economics.

Risk-sharing contracts in Colombia, particularly Prospective Global Payments (PGP) , demonstrate Auna's strategic flexibility. These contracts grew from 7% to 21% of Colombia revenue, shifting risk from volume-based fee-for-service to capitated payments. While this intentionally tempered revenue growth, it improved cash flow predictability and reduced exposure to government-intervened payers like Nueva EPS. This matters because Auna's pivot to risk-sharing means it profits from managing population health efficiently rather than fighting for reimbursement.

The integrated platform's network effects create a self-reinforcing cycle. Health plan membership drives patient volume to Auna's facilities, which improves utilization and margins. Higher margins fund investments in technology and physician alignment, which improves outcomes and attracts more members. Peru's 10% membership growth and 4.4 percentage point improvement in capacity utilization exemplify this flywheel. Competitors without integrated plans must acquire patients through expensive marketing, putting them at a structural disadvantage.

Financial Performance & Segment Dynamics: Evidence of Strategy Working

Consolidated 2025 results tell a story of transition. Revenue grew 4% FX-neutral to approximately $1.20 billion USD, while adjusted EBITDA declined 3% to PEN 917 million. The EBITDA decline reflects Mexico's operational challenges and Colombia's high 2024 comparison base, but the underlying cash generation improved. Free cash flow surged 35% to PEN 582 million, and the cash position increased 42% to PEN 335 million. This divergence between EBITDA and cash flow suggests that working capital management and capital efficiency are improving.

Peru's performance validates the AunaWay model's potential. Q4 revenue increased 11% and adjusted EBITDA rose 14%. The oncology MLR's six consecutive quarterly declines to 48.5% demonstrates that scale and standardization drive cost containment. Total capacity utilization improved 4.4 percentage points, indicating that Auna is filling its existing asset base before requiring major capital expenditures. This shows the model can generate both growth and margin expansion simultaneously.

Mexico's trajectory reveals an inflection point. Q4 revenue was unchanged from Q3, signaling stabilization. More importantly, surgery volumes grew for two consecutive quarters, oncology and cardiology services increased 48% versus Q2, and Out-of-Pocket revenues reached 12% of total Mexico revenue. The Q4 EBITDA decline reflects the final quarter of legacy contract terms and physician realignment costs. The new ISSSTELEON contract for 2026 includes a 30% price increase and gives Auna control over pharma and device prescription. This implies that Mexico's EBITDA margin could recover 200-300 basis points in 2026 as volumes return and pricing improves.

Colombia's strategy of prioritizing cash flow quality is working. Risk-sharing models now represent 21% of segment revenue, while revenue from intervened payer Nueva EPS fell from 20% to 13% of segment revenue. This shift shows Auna is deliberately sacrificing top-line growth for cash flow predictability and reduced credit risk—a trade-off that strengthens the long-term defensibility of the business.

The balance sheet transformation is a critical development. The $825 million refinancing extended maturities, reduced the blended interest rate by over 100 basis points to approximately 11.5%, and increased short-term liquidity. With 56% of debt now in local currency and 85% of USD debt hedged to the Peruvian sol, Auna has mitigated FX risk. Net debt-to-EBITDA stands at 3.6x, with management targeting 3x in the medium term. The 35% free cash flow growth demonstrates that Auna can service debt while funding growth.

Outlook, Management Guidance, and Execution Risk

Management's 2026 guidance—12% FX-neutral revenue growth and 12% adjusted EBITDA growth—represents a significant shift from 2025's cautious stance. This signals that the operational issues are being resolved and the AunaWay model's benefits are becoming visible.

The guidance's key assumption is Mexico's recovery. Management expects to recover margin contraction in 2026, driven by the improved ISSSTELEON contract and preferred provider status with major insurers. Early 2026 data supports this: surgery volumes are up, oncology services are growing, and occupancy reached 41% in February. The Out-of-Pocket segment is targeted to reach 20% of Mexico revenue by end-2026. This matters because Out-of-Pocket carries high margins, implying that mix shift alone could drive significant margin expansion.

The Sojitz Corporation of America MOU represents a potential catalyst. Management acknowledges gaining traction on a partnership that could fund the $500 million Mexico expansion plan over 3-5 years. External capital would accelerate growth without increasing leverage, addressing a key constraint on Auna's valuation. If Sojitz commits capital, it validates the AunaWay model's scalability and could drive a re-rating.

The Peru's Trecca project provides long-term visibility. The Centro Ambulatorio Trecca, a large outpatient facility serving 3 million EsSalud patients, begins operations in H2 2028 and will represent a significant portion of Peru's business at maturity. Construction costs are reimbursed by EsSalud through progress certificates, making it debt-neutral. This locks in a decade of high-margin, government-backed revenue growth, providing a floor for Peru's earnings power.

Risks and Asymmetries: What Could Break the Thesis

The most material risk is Mexico's execution. While early 2026 data is positive, the recovery remains nascent. If surgery volumes stall or the ISSSTELEON contract's benefits fail to materialize, the 12% EBITDA growth guidance may be difficult to reach. Mexico represents approximately 30% of revenue and was the primary driver of 2025's EBITDA decline. A failure to recover would suggest the AunaWay model faces structural barriers in Mexico's healthcare culture.

Colombia's political and regulatory environment remains a factor. While management does not expect significant changes in the short term, government intervention in payers creates reimbursement uncertainty. The company's strategy of constraining services to certain payers reduces risk but also caps growth. If political shifts lead to more aggressive price controls, Colombia's cash flow improvements could be impacted.

Leverage still constrains strategic options. At 3.6x net debt-to-EBITDA, Auna remains more leveraged than many healthcare peers. The refinancing helped, but interest expense still consumes a significant portion of cash flow, limiting the pace of deleveraging. If EBITDA growth disappoints, leverage could remain elevated, keeping valuation multiples compressed.

The Sojitz partnership's uncertainty creates an asymmetry. If the MOU converts to a concrete investment, Auna could accelerate Mexico expansion and potentially enter new markets. If it falls through, Auna must fund growth internally, potentially slowing expansion. The stock's current valuation suggests the market is pricing in these execution risks.

Valuation Context: Pricing in Execution Risk

At $5.66 per share, Auna trades at a market capitalization of $418.91 million and an enterprise value of $1.46 billion. The valuation metrics reveal a market pricing in skepticism: EV/EBITDA of 6.13x and price-to-free-cash-flow of 3.06x. These multiples are low for a healthcare company targeting double-digit growth.

The debt-to-equity ratio of 2.23x and net debt-to-EBITDA of 3.6x explain some of the discount, but the refinancing has improved the risk profile. With 56% of debt in local currency and 85% of USD debt hedged, FX risk is mitigated. The company generated PEN 582 million in free cash flow against PEN 459 million in net finance costs, showing it can service its debt while funding growth.

The integrated model's economics typically command a premium. Peru's 22.7% EBITDA margins and record-low MLR demonstrate pricing power. Mexico's margin compression is being addressed with a clear path to recovery. The 12% growth guidance, if achieved, would likely merit a higher EV/EBITDA multiple than the current level.

Conclusion: A Turnaround Story with Asymmetric Risk/Reward

Auna's investment thesis hinges on the AunaWay model's validation in Mexico after 2025's implementation challenges. The evidence suggests stabilization is occurring: surgery volumes are growing and the ISSSTELEON contract provides improved pricing and cost control. Peru's consistent performance and the debt-neutral Trecca project provide a stable earnings foundation. The $825 million refinancing has transformed the capital structure, enabling the Mexico expansion plan.

The key variables to monitor are Q1 2026 Mexico volume trends and the Sojitz partnership's progression. If Mexico's occupancy continues rising and oncology margins expand, the 12% EBITDA growth guidance appears achievable. Sojitz capital would accelerate expansion and validate the model's scalability, likely triggering a re-rating from current levels.

The risk/reward is asymmetric. Downside is supported by Peru's predictable cash flows and the refinanced balance sheet. Upside could be substantial if the AunaWay model delivers on its promise of transforming Latin American healthcare. For investors looking past recent operational noise, Auna offers a combination of low valuation and a clear path to regional healthcare leadership.